Davis Polk advised the joint book-running managers in connection with the $226.3 million public offering of common stock of Xencor, Inc. The common stock is listed on the NASDAQ Global Market under the symbol “XNCR.”
Based in Monrovia, California, Xencor, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody therapeutics for the treatment of autoimmune and allergic diseases, cancer and other conditions.
The Davis Polk corporate team included partner Bruce K. Dallas and associates Amy Tu and Benson Richards. The tax team included partner Rachel D. Kleinberg and associate M. Brett Cameron. The intellectual property and technology team included counsel Michelle Ontiveros Gross and associate Jason J. Bang. Associate Sijia Cai provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.